Evidence map›Paper›PMID 28828171›Full record

ArticleInternational journal of organ transplantation medicine2017

Serum sTWEAK and FGF-23 Levels in Hemodialysis and Renal Transplant Patients.

H Eskandari Naji, A Ghorbanihaghjo, H Argani, S Raeisi, J Safa, A H Alirezaei, N Rashtchizadeh

Open access · greenAbstract read

In one paragraph

Article in International journal of organ transplantation medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it

0cells of the map it votes in

6citing papers in PubMed

1.2field-weighted citation impact, top 21% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

Midnight Cortisol is Associated with Changes in Systolic Blood Pressure and Diabetic Neuropathy in Subjects with Type 1 Diabetes Undergoing Simultaneous Kidney-Pancreas Transplantation.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
Article
Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients.Clinical kidney journal · 2023
Article
Effects ofEvidence-based complementary and alternative medicine : eCAM · 2022
Article
TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?Clinical science (London, England : 1979) · 2019
Review
Evaluation of Serum Interleukin-6 Levels in the Renal Transplant Recipients: A Systematic Review and Meta-Analysis of Case-Control Studies.Open access Macedonian journal of medical sciences · 2019
Review
Mineral and Bone Disease in Kidney Transplant Recipients.Current osteoporosis reports · 2018
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

H Eskandari NajiDepartment of Clinical Biochemistry and Laboratory Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

A GhorbanihaghjoDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

H ArganiDepartment of Urology, Shahid Modarres Hospital, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

S RaeisiDivision of Clinical Laboratory, Children's Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.

J SafaDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

A H AlirezaeiDepartment of Urology, Shahid Modarres Hospital, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

N RashtchizadehBiotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Tabriz University of Medical Sciences · IRBiotechnology Research Center · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKidney transplantation is the treatment of choice for patients with end-stage renal disease.

objectiveTo evaluate the changes in serum soluble TNF-like weak inducer of apoptosis (sTWEAK) and fibroblast growth factor 23 (FGF-23) in hemodialysis (HD) patients and renal transplant recipients (RTR).

methodsSerum samples were obtained from 30 patients on chronic HD, 30 RTRs, and 30 normal controls. Biochemical factors, sTWEAK, FGF-23, and interlukin-6 (IL-6) were measured by standard methods.

resultsSerum levels of sTWEAK in RTRs were significantly higher than those in the HD patients (p=0.025); RTR and HD patients had significantly lower sTWEAK levels than the controls (p=0.001 and p= 0.038, respectively). Serum levels of FGF-23 in HD patients were significantly (p=0.001) higher than those in the RTR; the level was higher in both studied groups compared to that in the controls (p=0.001 for both groups). The mean serum level of IL-6 in HD was significantly higher than that in RTR patients (p=0.013). IL-6 levels in both groups were significantly higher than those in controls (p=0.001 and p= 0.012, respectively). In HD group a negative correlation was found between FGF-23 and sTWEAK (r= 0.375, p=0.041); there were also a significant correlation between FGF-23 and IL-6 (r= 0.480, p= 0.007) and between IL-6 and sTWEAK (r= 0.409, p=0.025).

conclusionWe found that serum sTWEAK is decreased and FGF-23 is increased in HD and RTR groups comparing with the control group. However, further studies are needed to shed light over their direct role on atherosclerosis and cardiovascular outcomes.

Indexed as

Fibroblast growth factor 23 [Supplementary Concept]Kidney transplantationRenal dialysissTWEAKTL1 cytokine [Supplementary Concept]

Identifiers

PMID28828171

PMCPMC5549008

OpenAlexW2977502200

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.